Cogent Biosciences, Inc. (COGT)

Cogent Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	-	7.87
Revenue Growth (YoY)	-	-	-	-	-65.02%
Cost of Revenue	-	-	-	-	25.74
Gross Profit	-	-	-	-	-17.87
Selling, General & Admin	43.28	34.38	26.21	19.64	17.42
Research & Development	232.66	173.76	121.63	55.91	-
Operating Expenses	275.94	208.13	147.84	75.55	17.42
Operating Income	-275.94	-208.13	-147.84	-75.55	-35.29
Interest & Investment Income	18.09	13.08	3.99	0.47	0.14
Other Non Operating Income (Expenses)	1.99	2.64	3.61	2.81	-0.25
EBT Excluding Unusual Items	-255.86	-192.41	-140.24	-72.27	-35.39
Gain (Loss) on Sale of Assets	-	-	-	-	7.49
Pretax Income	-255.86	-192.41	-140.24	-72.27	-74.81
Earnings From Continuing Operations	-255.86	-192.41	-140.24	-72.27	-74.81
Net Income	-255.86	-192.41	-140.24	-72.27	-74.81
Preferred Dividends & Other Adjustments	-	-	-	-	104.4
Net Income to Common	-255.86	-192.41	-140.24	-72.27	-179.21
Shares Outstanding (Basic)	104	80	59	39	11
Shares Outstanding (Diluted)	104	80	59	39	11
Shares Change (YoY)	30.36%	35.54%	51.89%	249.52%	45.42%
EPS (Basic)	-2.46	-2.41	-2.38	-1.87	-16.17
EPS (Diluted)	-2.46	-2.41	-2.38	-1.87	-16.17
Free Cash Flow	-208.36	-156.42	-125.5	-60.48	-35.85
Free Cash Flow Per Share	-2.00	-1.96	-2.13	-1.56	-3.23
Gross Margin	-	-	-	-	-227.00%
Operating Margin	-	-	-	-	-448.34%
Profit Margin	-	-	-	-	-2276.81%
Free Cash Flow Margin	-	-	-	-	-455.47%
EBITDA	-273.49	-205.86	-147	-75.4	-34.57
D&A For EBITDA	2.45	2.27	0.84	0.15	0.72
EBIT	-275.94	-208.13	-147.84	-75.55	-35.29

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q